SCHEMBL12469738

SCHEMBL12469738

O=[N+]([O-])c1cc(C2CCC(c3ccc(Cl)c([N+](=O)[O-])c3)N2c2ccc(OCc3ccccc3)cc2)ccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ATM Q13315 1/20 0.43
AR P10275 1/20 0.41
SIRT1 Q96EB6 1/20 0.40
KDM1A O60341 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
POLB P06746 1/20 0.39
PIN1 Q13526 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
PTGES O14684 1/20 0.39
VCAM1 P19320 1/20 0.39
BCL2 P10415 1/20 0.39
MCL1 Q07820 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239658 1.00 KMT2A (0.43) KMT2AMEN1NPC1RAB9AATM
SCHEMBL240751 0.86 SMN1; SMN2 (0.42) KMT2AMEN1NPC1KDM1ASMN1; SMN2
SCHEMBL241050 0.85 MAPT (0.42) KMT2AMEN1SMN1; SMN2LMNAPOLB
SCHEMBL240492 0.82 KMT2A (0.44) KMT2AMEN1NPC1KDM1ASMN1; SMN2
SCHEMBL240689 0.82 ALDH1A1 (0.36) KMT2AMEN1NPC1SMN1; SMN2LMNA
SCHEMBL240878 0.80 KAT2B (0.42) KMT2AMEN1NPC1SMN1; SMN2LMNA
SCHEMBL18653275 0.79 ALDH1A1 (0.46) KMT2AMEN1NPC1KDM1ASMN1; SMN2
SCHEMBL238882 0.79 KAT2B (0.41) KMT2AMEN1NPC1SMN1; SMN2LMNA
SCHEMBL810842 0.78 MEN1 (0.53) KMT2AMEN1NPC1RAB9AATM
SCHEMBL29463873 0.78 MEN1 (0.53) KMT2AMEN1NPC1RAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2678334-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2014-01-01 EP disclosed
EP-2627651-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2013-08-21 EP disclosed
WO-2012116257-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. (US) 2012-08-30 WO disclosed
WO-2012051361-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-19 WO disclosed